Foghorn Therapeutics (FHTX) reported continued net losses for the nine months ended September 30, 2025, but showed significant operational improvement.
Financial Performance & Liquidity: Net Loss narrowed substantially to (\(52.6 million) from (\)67.1 million) year-over-year (YOY), improving diluted loss per share to (\(0.84). Total operating expenses decreased 14.5% to \)84.2 million, primarily driven by a 14.3% reduction in Research and Development (R&D) expenses (\(63.4 million YTD). Collaboration Revenue, largely tied to the Lilly Agreement, increased to \)21.7 million. The Company ended th
...